Holen Sie sich die Stockscreener-App
572.60
2.67%
14.87
Handel nachbörslich:
571.68
-0.92
-0.16%
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
How sentiment analysis helps forecast Regeneron Pharmaceuticals Inc.Dividend Hike & Weekly Breakout Watchlists - newser.com
Regeneron Pharmaceuticals Shapes Nasdaq Futures with Market Impact - Kalkine Media
Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Regeneron’s Q3 2025 Earnings: What to Expect - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
2 Stocks Down 17% and 21% to Buy Right Now - Yahoo Finance
Regeneron, Scholar Rock Approvals In Limbo As FDA Hits Novo Plant - insights.citeline.com
Canaccord Genuity reiterates Buy rating on Regeneron stock despite EYLEA headwinds - Investing.com
Morningstar Investment Management LLC Makes New $608,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Will breakout in Regeneron Pharmaceuticals Inc. lead to full recovery2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
FDA approves Celltrion's Eylea bisoimilar - Eyes On Eyecare
Hudson Capital Management LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Vanguard Personalized Indexing Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Top chart patterns to watch in Regeneron Pharmaceuticals Inc.Bull Run & Real-Time Volume Spike Alerts - newser.com
Is Regeneron Pharmaceuticals Inc. (RGO) stock ideal for retirement investorsFed Meeting & Weekly High Return Stock Forecasts - newser.com
Predicting Regeneron Pharmaceuticals Inc. trend using moving averagesWeekly Profit Summary & Consistent Return Investment Signals - newser.com
Regeneron’s Gene Therapy DB-OTO Improves Speech Perception in Children With Otoferlin-Related Hearing Loss - CGTLive®
Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss - Benzinga
Citigroup Maintains "Buy" Rating on REGN, Raises Price Target to $660 | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Detecting support and resistance levels for Regeneron Pharmaceuticals Inc.Weekly Gains Summary & High Conviction Buy Zone Picks - newser.com
Why Are Regeneron And Scholar Rock Shares Falling On Monday? - Stocktwits
Regeneron plans FDA filing based on latest DB-OTO data - The Pharma Letter
Using data filters to optimize entry into Regeneron Pharmaceuticals Inc.Gap Up & Weekly Setup with High ROI Potential - newser.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down on Analyst Downgrade - MarketBeat
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss - TradingView
Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge - Yahoo Finance
Regeneron Readies FDA Run for Hearing Loss Gene Therapy That Could 'Transform Patients’ Lives' - BioSpace
Cell And Gene Therapy For Multiple Myeloma Market Positioned - openPR.com
Biosimilar Fights Regeneron Bid To Block Eye Treatment - Law360
A New Gene Therapy for Deafness Looks Promising - Bloomberg.com
Cwm LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN) Stock Analysis: A 27.79% Upside Beckons Investors Amidst Biotechnology Innovations - DirectorsTalk Interviews
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today - MSN
Cantor Fitzgerald Brokers Raise Earnings Estimates for REGN - MarketBeat
Regeneron (REGN) Gene Therapy Shows Promising Results for Geneti - GuruFocus
How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise? - Yahoo Finance
Regeneron Pharma Reports Promising Results For DB-OTO Gene Therapy In Genetic Hearing Loss - Nasdaq
Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy - BioPharma Dive
Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss - MarketScreener
GW Henssler & Associates Ltd. Raises Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meritage Portfolio Management Acquires Shares of 11,455 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Hobbs Group Advisors LLC - MarketBeat
606 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Clear Creek Financial Management LLC - MarketBeat
Prime Capital Investment Advisors LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Is Up After FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CSCC - simplywall.st
Morgan Stanley Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
JB Capital LLC Invests $3.62 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Aberdeen Group plc Has $106.97 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Lmcg Investments LLC - MarketBeat
Callan Family Office LLC Has $3.17 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Morgan Stanley Lowers Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals Inc. stock daily chart insightsRisk Management & Precise Buy Zone Tips - newser.com
Is Regeneron at a Turning Point After 43% Drop and FDA Eye Drug Approval News? - simplywall.st
Will Regeneron Pharmaceuticals Inc. continue its uptrend2025 Market Sentiment & Weekly Watchlist for Hot Stocks - newser.com
What If You Were Missing The Value In Regeneron Pharmaceuticals Stock? - Forbes
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Sysmex (SSMXF) - The Globe and Mail
Can you recover from losses in Regeneron Pharmaceuticals Inc.July 2025 Macro Moves & High Conviction Buy Zone Alerts - newser.com
Can Regeneron Pharmaceuticals Inc. (RGO) stock deliver consistent EPS growthPortfolio Risk Summary & Verified Entry Point Signals - newser.com
Leo Wealth LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Forecasting Regeneron Pharmaceuticals Inc. price range with options dataEntry Point & Daily Oversold Bounce Ideas - newser.com
How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks? - MSN
Libtayo’s CSCC Label Expansion Broadens Practitioner Base - insights.citeline.com
Regeneron Pharmaceuticals Hits Day Low of $561 Amid Price Pressure - Markets Mojo
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients - Benzinga
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’ - Stocktwits
0.95%
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):